Abigail Eubank
Primary Care · Hendersonville, TNNPI 1588861207
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 68.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2021 at $5,448 and has fallen 84.3% since, to $856 in 2025. Among primary care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Novo Nordisk$505
- Pfizer$351
- Biohaven Pharmaceutical Holding Company Ltd.$222
- Takeda Pharmaceuticals U.S.A., Inc.$187
- Lilly USA, LLC$175
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$4,95057%
- Food & beverage$3,72142%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $5,985 |
| Novo Nordisk | 38 | $505 |
| Pfizer | 22 | $351 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $187 |
| Lilly USA, LLC | 9 | $175 |
| Novartis | 9 | $166 |
| Amgen | 7 | $149 |
| Abbott | 3 | $136 |
| Idorsia Pharmaceuticals US Inc | 4 | $125 |
| Sumitomo Pharma America, Inc. | 5 | $105 |
| Astellas Pharma US Inc | 2 | $102 |
| Merck | 6 | $81 |
| Corcept Therapeutics | 3 | $61 |
| Amarin Pharma, Inc. | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| AstraZeneca(2 entities) | 3 | $51 |
| Shield Therapeutics Inc | 2 | $34 |
| Alkermes, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$4,950
How this compares
$8,756 in reported general payments places this provider in the 95th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $129,643 |
| XareltoRivaroxaban | 62 | $50,418 |
| MounjaroTirzepatide | 19 | $41,527 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $38,329 |
| EliquisApixaban | 44 | $34,336 |
| JardianceEmpagliflozin | 32 | $29,444 |
| MyrbetriqMirabegron | 32 | $22,382 |
| JanuviaSitagliptin Phosphate | 16 | $18,603 |
| FarxigaDapagliflozin Propanediol | 14 | $16,526 |
| BelsomraSuvorexant | 27 | $14,739 |
| Repatha SureclickEvolocumab | 25 | $13,592 |
| QuliptaAtogepant | 12 | $12,276 |
| GemtesaVibegron | 16 | $7,707 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $6,680 |
| SynthroidLevothyroxine Sodium | 57 | $4,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $505 | $129,643120 claims |
| Johnson & JohnsonXarelto | $17 | $50,41862 claims |
| Lilly USA, LLCMounjaro | $175 | $41,52719 claims |
| PfizerEliquis | $351 | $34,33644 claims |
| MerckJanuvia, Belsomra | $81 | $33,34243 claims |
| Astellas Pharma US IncMyrbetriq | $102 | $22,38232 claims |
| AbbVieQulipta, Synthroid | $5,985 | $17,02169 claims |
| AstraZenecaFarxiga | $51 | $16,52614 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $105 | $7,70716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 primary care providers in Tennessee.
Other primary care in Hendersonville
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Reena BhaktaMurfreesboro$12K
- Ryan HartmanNashville$11K
- Martha LemonsBrentwood$11K
- Corey ClelandSevierville$9K
- Katie JohnsonClarksville$8K
- Janice BassManchester$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.